Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.
作者信息
Gurney Mark, Baranwal Anmol, Rosenthal Allison, Kharfan-Dabaja Mohamed A, Kenderian Saad S, Lin Yi, Shah Mithun Vinod
机构信息
Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Cancer Centers of Southwest Oklahoma, Lawton.
出版信息
JAMA Oncol. 2024 Apr 1;10(4):532-535. doi: 10.1001/jamaoncol.2023.7182.
Abstract
摘要
相似文献
1
Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.
JAMA Oncol. 2024 Apr 1;10(4):532-535. doi: 10.1001/jamaoncol.2023.7182.
2
Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma-A Call for Equal Opportunity.
JAMA Oncol. 2023 Mar 1;9(3):297-298. doi: 10.1001/jamaoncol.2022.6834.
3
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.
Balkan Med J. 2025 Jul 1;42(4):301-310. doi: 10.4274/balkanmedj.galenos.2025.2025-4-25.
4
Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy.
Nat Cancer. 2025 Apr;6(4):647-665. doi: 10.1038/s43018-025-00927-0. Epub 2025 Mar 17.
5
Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.
Bone Marrow Transplant. 2020 Nov;55(11):2215-2218. doi: 10.1038/s41409-020-0930-5. Epub 2020 May 9.
6
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
Lancet Haematol. 2025 May;12(5):e365-e375. doi: 10.1016/S2352-3026(25)00048-1. Epub 2025 Apr 12.
7
Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res. 2025 Mar 17;31(6):1163-1171. doi: 10.1158/1078-0432.CCR-24-2753.
8
Long-term outcomes following CAR T cell therapy: what we know so far.
Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.
9
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006522.
10
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11.
引用本文的文献
1
Deep insight into cytokine storm: from pathogenesis to treatment.
Signal Transduct Target Ther. 2025 Apr 16;10(1):112. doi: 10.1038/s41392-025-02178-y.
2
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):88-115. doi: 10.1002/ajh.27655. Epub 2025 Mar 11.
3
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.
Bone Marrow Transplant. 2025 May;60(5):632-639. doi: 10.1038/s41409-025-02541-1. Epub 2025 Mar 1.
4
A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies.
Med Sci Monit. 2025 Feb 2;31:e948125. doi: 10.12659/MSM.948125.
5
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.
JAMA. 2024 Dec 10;332(22):1924-1935. doi: 10.1001/jama.2024.19462.
6
Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment.
Blood Cancer Discov. 2024 Nov 1;5(6):400-416. doi: 10.1158/2643-3230.BCD-24-0103.
7
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.
Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798.
8
Current progress in CAR-based therapy for kidney disease.
Front Immunol. 2024 Aug 20;15:1408718. doi: 10.3389/fimmu.2024.1408718. eCollection 2024.
9
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
Zotero 插件